6.
Duscharla D, Bhumireddy S, Lakshetti S, Pospisil H, Murthy P, Walther R
. Prostate Cancer Associated Lipid Signatures in Serum Studied by ESI-Tandem Mass Spectrometryas Potential New Biomarkers. PLoS One. 2016; 11(3):e0150253.
PMC: 4784901.
DOI: 10.1371/journal.pone.0150253.
View
7.
Deng M, Cao J, van der Kroft G, van Dijk D, Aberle M, Grgic A
. Inflammation-associated intramyocellular lipid alterations in human pancreatic cancer cachexia. J Cachexia Sarcopenia Muscle. 2024; 15(4):1283-1297.
PMC: 11294036.
DOI: 10.1002/jcsm.13474.
View
8.
LaPensee C, Mann J, Rainey W, Crudo V, Hunt 3rd S, Hammer G
. ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs. Endocrinology. 2016; 157(5):1775-88.
DOI: 10.1210/en.2015-2052.
View
9.
Nashed M, Chisholm J, Igal R
. Stearoyl-CoA desaturase activity modulates the activation of epidermal growth factor receptor in human lung cancer cells. Exp Biol Med (Maywood). 2012; 237(9):1007-17.
DOI: 10.1258/ebm.2012.012126.
View
10.
Schcolnik-Cabrera A, Chavez-Blanco A, Dominguez-Gomez G, Taja-Chayeb L, Morales-Barcenas R, Trejo-Becerril C
. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy. Expert Opin Investig Drugs. 2018; 27(5):475-489.
DOI: 10.1080/13543784.2018.1471132.
View
11.
Min H, Lim S, Chung B, Moon M
. Shotgun lipidomics for candidate biomarkers of urinary phospholipids in prostate cancer. Anal Bioanal Chem. 2010; 399(2):823-30.
DOI: 10.1007/s00216-010-4290-7.
View
12.
Butler L, Perone Y, Dehairs J, Lupien L, de Laat V, Talebi A
. Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020; 159:245-293.
PMC: 7736102.
DOI: 10.1016/j.addr.2020.07.013.
View
13.
Li X, Chen Y, Hu P, Huang W
. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther. 2014; 13(4):855-66.
PMC: 4084917.
DOI: 10.1158/1535-7163.MCT-13-0797.
View
14.
Del Boccio P, Pieragostino D, Di Ioia M, Petrucci F, Lugaresi A, De Luca G
. Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. J Proteomics. 2011; 74(12):2826-36.
DOI: 10.1016/j.jprot.2011.06.023.
View
15.
Aguirre-Portoles C, Feliu J, Reglero G, Ramirez de Molina A
. ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin-1-dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone. Mol Oncol. 2018; 12(10):1735-1752.
PMC: 6166002.
DOI: 10.1002/1878-0261.12367.
View
16.
Goto-Inoue N, Hayasaka T, Zaima N, Setou M
. Imaging mass spectrometry for lipidomics. Biochim Biophys Acta. 2011; 1811(11):961-9.
DOI: 10.1016/j.bbalip.2011.03.004.
View
17.
Dill A, Ifa D, Manicke N, Costa A, Ramos-Vara J, Knapp D
. Lipid profiles of canine invasive transitional cell carcinoma of the urinary bladder and adjacent normal tissue by desorption electrospray ionization imaging mass spectrometry. Anal Chem. 2009; 81(21):8758-64.
PMC: 2783352.
DOI: 10.1021/ac901028b.
View
18.
Mehta A, Ratre Y, Soni V, Shukla D, Sonkar S, Kumar A
. Orchestral role of lipid metabolic reprogramming in T-cell malignancy. Front Oncol. 2023; 13:1122789.
PMC: 10226149.
DOI: 10.3389/fonc.2023.1122789.
View
19.
Xiang X, Saha A, Wen R, Ruderman N, Luo Z
. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 2004; 321(1):161-7.
DOI: 10.1016/j.bbrc.2004.06.133.
View
20.
BLIGH E, Dyer W
. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37(8):911-7.
DOI: 10.1139/o59-099.
View